Arbutus Biopharma ABUS SEC Filings

NASDAQ ABUS
$3.82 +0.10 (+2.69%)
At close: Nov 10, 2026 · 4:00 PM EST
EDGAR Disclosures

SEC Filings

Source SEC EDGAR

Every SEC filing Arbutus Biopharma Corp (ABUS) has made, as reported on EDGAR — annual and quarterly reports, current reports, insider transactions and ownership disclosures. Filter by form group, form type or period, and open any filing or its index directly.

Form Type
# Form Type Form Group Accession Date Filing Index
110-QQuarterly & Annual Report0001447028-26-000064Nov 10, 2026 7:34 AM-
28-KCurrent Report0001171843-26-007311Nov 10, 2026 7:31 AM-
3SCHEDULE 13GBeneficial Ownership Report0002012383-26-003716Oct 27, 2026 9:25 PM
48-KCurrent Report0001171843-26-006753Oct 22, 2026 3:31 PM
5SCHEDULE 13GBeneficial Ownership Report0000895421-26-000284Oct 7, 2026 12:35 AM
64Insider Transaction0001447028-26-000061Oct 7, 2026 12:12 AM
74Insider Transaction0001447028-26-000060Oct 7, 2026 12:11 AM
84Insider Transaction0001447028-26-000059Oct 7, 2026 12:09 AM
94Insider Transaction0001447028-26-000058Oct 7, 2026 12:09 AM
10SCHEDULE 13DBeneficial Ownership Report0001140361-26-038693Oct 5, 2026 5:02 AM
114Insider Transaction0001140361-26-038692Oct 5, 2026 5:00 AM
12SC TO-IOthers0001104659-26-112579Oct 1, 2026 3:35 PM
13SC TO-IOthers0001104659-26-112115Sep 30, 2026 7:35 AM
144Insider Transaction0001447028-26-000053Sep 23, 2026 12:32 AM
154Insider Transaction0001447028-26-000052Sep 23, 2026 12:31 AM
164Insider Transaction0001447028-26-000051Sep 23, 2026 12:31 AM
174Insider Transaction0001447028-26-000050Sep 23, 2026 12:31 AM
18SCHEDULE 13GBeneficial Ownership Report0000921895-26-002494Sep 4, 2026 10:32 PM
19SC TO-IOthers0001104659-26-100002Aug 24, 2026 12:24 PM
20SC TO-COthers0001104659-26-099391Aug 21, 2026 12:04 PM
218-KCurrent Report0001104659-26-099390Aug 21, 2026 11:53 AM
22SCHEDULE 13GBeneficial Ownership Report0000895421-26-000222Aug 12, 2026 7:02 PM
2310-QQuarterly & Annual Report0001447028-26-000045Aug 12, 2026 11:31 AM
248-KCurrent Report0001171843-26-005442Aug 12, 2026 11:31 AM
258-KCurrent Report0001171843-26-004708Jul 16, 2026 11:31 AM
264Insider Transaction0001447028-26-000040Jun 10, 2026 8:05 PM
274Insider Transaction0001447028-26-000039Jun 10, 2026 8:05 PM
28S-8Prospectus0001447028-26-000027Jun 5, 2026 8:05 PM
298-KCurrent Report0001447028-26-000024May 27, 2026 8:01 PM
30SCHEDULE 13GBeneficial Ownership Report0001011438-26-000347May 15, 2026 9:29 PM
3110-QQuarterly & Annual Report0001447028-26-000021May 13, 2026 11:31 AM
328-KCurrent Report0001171843-26-003346May 13, 2026 11:31 AM
33SCHEDULE 13DBeneficial Ownership Report0000921895-26-001101Apr 28, 2026 9:54 PM
348-KCurrent Report0001171843-26-002458Apr 15, 2026 11:31 AM
35DEFA14AOthers0001140361-26-014624Apr 14, 2026 9:05 PM
36DEF 14AOthers0001140361-26-014623Apr 14, 2026 9:02 PM
37SCHEDULE 13DBeneficial Ownership Report0000921895-26-000973Apr 13, 2026 11:56 PM
388-KCurrent Report0001171843-26-001838Mar 23, 2026 11:31 AM
3910-KQuarterly & Annual Report0001447028-26-000017Mar 23, 2026 11:30 AM
408-KCurrent Report0001171843-26-001299Mar 3, 2026 9:16 PM
418-KCurrent Report0001171843-26-000979Feb 20, 2026 9:01 PM
42SCHEDULE 13GBeneficial Ownership Report0001011438-26-000149Feb 17, 2026 9:21 PM
43SCHEDULE 13GBeneficial Ownership Report0000895421-26-000041Feb 11, 2026 6:45 PM
448-KCurrent Report0001171843-26-000676Feb 6, 2026 9:01 PM
454Insider Transaction0001447028-26-000009Feb 2, 2026 1:21 AM
464Insider Transaction0001447028-26-000008Feb 2, 2026 1:21 AM
478-KCurrent Report0001171843-26-000303Jan 16, 2026 12:41 PM
488-KCurrent Report0001171843-25-007879Dec 11, 2025 1:00 PM
498-KCurrent Report0001171843-25-007256Nov 13, 2025 12:31 PM
5010-QQuarterly & Annual Report0001447028-25-000126Nov 13, 2025 12:31 PM
...

Arbutus Biopharma Corp SEC Filings API

Pull Arbutus Biopharma Corp's SEC filing index, with links to every filing and exhibit, into your own tools with the Business Quant SEC Filings API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/secfilings?ticker=ABUS&formtype=10-K,10-Q&api_key=YOUR_API_KEY